Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
A good example of that is Viking Therapeutics (NASDAQ: VKTX) . The company has been doing a lot of things well lately, and there's a lot of hope and optimism around the business. But all that may not be enough of a reason to invest in Viking Therapeutics. While the stock may look great to some investors right now, here's why it's not worth buying. The GLP-1 market could get crowded The bullish case around Viking's stock has to do with a promising drug it has in development, which investors are hopeful may generate billions in revenue for the business in the long run. VK2735 is a glucagon-like peptide 1 (GLP-1) receptor agonist which has shown in clinical trials that it can help people lose as much as 15% of their body weight, on average. And the pill version has also been achieving promising results in early trials. But even if the drug obtains approval in a few years and comes to market, the GLP-1 weight-loss market could be crowded by then. Not only are there big names such
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
- Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes AssociationPR Newswire
- Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- Here's Why Viking Therapeutics (VKTX) Stock Skyrocketed in Q1 [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 4/24/24 - Beat
VKTX
Sec Filings
- 6/4/24 - Form 8-K
- 5/23/24 - Form 8-K
- 5/23/24 - Form S-8
- VKTX's page on the SEC website